FDA has published consumer-facing concerns about unapproved GLP-1 related drugs used for weight loss, including compounded products and illegally marketed research-labeled vials. This article extends our compounding-versus-approval literacy to the incretin category. It is not legal advice for pharmacies and not medical advice for patients.
Start from the approved baseline
When a conversation mentions semaglutide or tirzepatide, ask whether the speaker means a specific FDA-approved brand. That question alone removes a large share of confusion.
What FDA’s unapproved GLP-1 page emphasizes
FDA discusses quality and safety concerns with certain compounded and unapproved products, warns about research-only marketing directed at consumers, and specifically addresses substances such as retatrutide that are not eligible for the compounding pathways it describes.
Those statements are literacy tools for readers evaluating online offers. They are not a substitute for speaking with a clinician about personal care.
Next reads on Viral Peptides
Continue with compounded vs approved peptide medicines, retatrutide investigational status, and what research-use-only means.
Links back to the Safety & Guides hub
This article sits under peptide safety education. Return there for disclaimer boundaries, identity-and-purity literacy, and the broader compounding-versus-approval framework. Status detail for named incretin molecules continues in peptide research and science.
